Novo Nordisk A/S (NYSE:NVO) Downgraded by StockNews.com to Buy

Novo Nordisk A/S (NYSE:NVO - Get Free Report) was downgraded by investment analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a note issued to investors on Friday.

Several other equities research analysts have also commented on NVO. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Finally, BNP Paribas raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Moderate Buy" and a consensus target price of $145.25.

Novo Nordisk A/S Stock Down 2.3 %

Shares of NYSE:NVO traded down $1.76 during mid-day trading on Friday, hitting $73.57. 8,872,312 shares of the company traded hands, compared to its average volume of 5,438,701. The stock has a market cap of $330.15 billion, a P/E ratio of 22.36, a P/E/G ratio of 0.90 and a beta of 0.42. The stock has a 50-day moving average price of $83.01 and a two-hundred day moving average price of $99.94. Novo Nordisk A/S has a 12-month low of $73.80 and a 12-month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NVO. Center for Financial Planning Inc. lifted its holdings in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL increased its stake in shares of Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $28,000. Park Square Financial Group LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $29,000. Finally, Transce3nd LLC bought a new position in Novo Nordisk A/S in the 4th quarter worth approximately $33,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.